Physician profile
Robert C Black
NPI 1457644668
$6,948.48
in general payments reported to CMS, 2019-2025
13 companies · $302 in 2025
The $302 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,464 · 2020: $14.95 · 2023: $104 · 2024: $64.02 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $270 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $269.85 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $6,346.69 | 2019 | |
| Seagen INC. | $130.74 | 2023-2025 | Adcetris |
| Sobi, INC | $124.61 | 2025 | |
| Pharmacosmos Therapeutics INC. | $64.02 | 2024 | Monoferric |
| Genentech USA, INC. | $61.83 | 2019 | |
| Celgene Corporation | $44.11 | 2019-2025 | Reblozyl |
| Pfizer INC. | $37.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $29.58 | 2023 | Imfinzi |
| Mirati Therapeutics, INC. | $28.67 | 2023 | Krazati |
| Merck Sharp & Dohme LLC | $26.78 | 2019 | |
| Geron Corporation | $23.87 | 2025 | Rytelo |
| Incyte Corporation | $15.28 | 2023 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $14.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.